ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 062

Evaluating the Relationship Between an Electronic Transition Planning Tool and Transition Success in a Pediatric Rheumatology Clinic

Karissa Chesky1, Kyla Blasingame1, Jimin Kim1, Charles Lee2, Alonzo Needum1, Miriah Gillispie-Taylor3 and Tiphanie Vogel4, 1Baylor College of Medicine, 2Baylor College of Medicine, Houston, TX, 3Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 4Baylor College of Medicine/Texas Children's Hospital

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Thursday, March 19, 2026

Title: Posters: Quality, Health Services, and Education Research I

Session Time: 6:00PM-7:00PM

Background/Purpose: Young adults with chronic health conditions deserve an intentional transition from pediatric to adult care. We have developed a longitudinal process to standardize transfer of care of patients from pediatric to adult rheumatology providers. Elements of the process include utilization of a Transition Planning Tool (TPT)—an electronic medical record (EMR)-based flowsheet with 13 core components designed to assess patients’ knowledge, skills and ability to manage their own health—and a novel transition success score. Here, we assess if there is correlation between application of the TPT and successful transition.

Methods: We retrospectively reviewed the EMRs of a cohort of patients that transitioned out of our pediatric rheumatology clinic between 2017-2024. We ascertained TPT utilization rates, identified attainment of any TPT components, and calculated transition success scores. Our transition success score, created internally, includes four factors related to attendance at adult visits, medication refills with the new adult provider, and the absence of rheumatology-related emergency department visits/admissions in the first year after the final pediatric appointment. Patients must achieve all 4 components to have successful transition. GraphPad Prism was used for statistical analysis (Mann-Whitney).

Results: From 2017-2024 we identified 198 patients able to be scored for transition success. The average age at transition was 18.7±1 years, and the most common diagnoses were lupus (84/198, 47%) and juvenile arthritis (68/198, 34%). Pediatric providers utilized the TPT at least once with 178/198 (90%) of transitioned patients. In these 178, the TPT was utilized a median of 5 times per patient, however, there was a broad range as the TPT was only used once with 21, but more than 10x with 15 (IQR 3-7). Among the 157/178 (88%) patients with at least two TPT uses, TPT use spanned across a median of 2.6 (IQR 1.6-4.1) years. While 83/178 (47%) patients had the TPT used at the final pediatric rheumatology visit, among the other 95 patients the TPT was last used a median of 8.5 months prior to transfer of care, and actually ranged up to 4.1 years prior. Providers indicated that patients accomplished a median of 8 (IQR 4-11) of the 13 core TPT components (range 0-13) at any point during their pediatric rheumatology care. There were no differences in the average number of times the TPT was used (5.6 v 5.4, p=0.87) or in the number of TPT components fulfilled (7.6 v 7.1, p=0.35) between patients who were scored as transitioning successfully or not.

Conclusion: We have developed a structured transition process that incorporates a TPT to guide intentional transition planning for young adults with rheumatic disease. Providers are encouraged, but not required, to use the TPT. In this initial evaluation, there was no significant association between TPT use or accomplishment of TPT components and transition success. Future analyses will evaluate whether particular TPT components are predictive of transition success and if regular use of the TPT across time can improve transition outcomes.


Disclosures: K. Chesky: None; K. Blasingame: None; J. Kim: None; C. Lee: None; A. Needum: None; M. Gillispie-Taylor: None; T. Vogel: AstraZeneca, 5, Moderna, 2, Novartis, 2, Pediatric provider acknowledgment following healthcare transfer is inconsistently documented. This process gap highlights the need for standardized EH, 12, site PI, Pfizer, 2, Takeda, 6, UCB, 1.

To cite this abstract in AMA style:

Chesky K, Blasingame K, Kim J, Lee C, Needum A, Gillispie-Taylor M, Vogel T. Evaluating the Relationship Between an Electronic Transition Planning Tool and Transition Success in a Pediatric Rheumatology Clinic [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/evaluating-the-relationship-between-an-electronic-transition-planning-tool-and-transition-success-in-a-pediatric-rheumatology-clinic/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-the-relationship-between-an-electronic-transition-planning-tool-and-transition-success-in-a-pediatric-rheumatology-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology